AMGN - Amgen Inc.
170.00 +0.31 (0.18%)
After hours: 5:25PM EDT
| Previous Close | 168.39 |
| Open | 169.77 |
| Bid | 169.90 x 800 |
| Ask | 169.68 x 800 |
| Day's Range | 168.68 - 170.02 |
| 52 Week Range | 166.30 - 210.19 |
| Volume | 1,922,705 |
| Avg. Volume | 2,880,420 |
| Market Cap | 103.5B |
| Beta (3Y Monthly) | 0.90 |
| PE Ratio (TTM) | 13.53 |
| EPS (TTM) | 12.54 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 5.80 (3.23%) |
| Ex-Dividend Date | 2019-05-16 |
| 1y Target Est | 206.10 |
- PR Newswire•7 hours ago
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.
- Insider Monkey•8 hours ago
Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending
It's been a rather green day on Wall Street as all three major indexes are positive. The Dow Jones is up over 150 points while the S&P 500 is up 0.84%. Among the stocks traders are watching include Apple Inc. (NASDAQ:AAPL), Biogen Inc. (NASDAQ:BIIB), Amgen, Inc. (NASDAQ:AMGN), Deckers Outdoor Corp (NASDAQ:DECK), and Diamondback Energy Inc (NASDAQ:FANG). Let's analyze why each stock is […]
- Benzinga•2 days ago
Medicines Company Rallies On Positive LDL Cholesterol Study Results
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
- Zacks•2 days ago
Ligand Grants Preclinical Candidate Rights to UK-based Firm
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
- Motley Fool•4 days ago
Who Had the Better Quarter: Gilead Sciences or Amgen?
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
- TheStreet.com•5 days ago
Bulls Make Money, Bears Make Money and Hogs Get Slaughtered, Jim Cramer Says
That's Rule No. 5 of his '5 Rules for Trimming Your Winning Positions.'
- Investor's Business Daily•5 days ago
Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
- PR Newswire•5 days ago
Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
- Motley Fool•5 days ago
Here's Why Mirati Therapeutics Is Surging Today
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
- Benzinga•5 days ago
What's Triggering The Rise In Mirati Shares?
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN ) KRAS G12C inhibitor abstract showed promising ...
- Barrons.com•6 days ago
Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
- PR Newswire•6 days ago
Amgen Showcases Oncology Pipeline At ASCO 2019
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
- GuruFocus.com•6 days ago
Insulet and West Pharma Proven Winners in Growing Wearable Devices Market
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
- Motley Fool•7 days ago
3 Stocks With Big News Coming at ASCO 2019
These cancer drug developers could report market-moving news soon.
- Benzinga•7 days ago
The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
- Zacks•7 days ago
AbbVie Settles Humira Litigation With Boehringer Ingelheim
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
- Zacks•8 days ago
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
- Simply Wall St.•8 days ago
Introducing Amgen (NASDAQ:AMGN), A Stock That Climbed 50% In The Last Five Years
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•8 days ago
Top Stock Reports for Amgen, Altria & Booking Holdings
Top Stock Reports for Amgen, Altria & Booking Holdings
- Benzinga•11 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
- PR Newswire•11 days ago
Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...
- Reuters•11 days ago
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.
- Zacks•12 days ago
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
- Zacks•14 days ago
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
